Revelation Biosciences Inc
revbiosciences.comWhat Do They Do?
Develops Gemini-based drug candidates for treating acute kidney injury and chronic kidney disease.
10-K for FY2025, filed Feb 26, 2026Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary…View ↗
Revelation is focused on developing potentially high-value products to address significant, unmet medical needs. Revelation’s lead product…View ↗
Our lead Gemini programs have been derisked with preclinical and clinical data and are focused on disorders involving the kidneys including…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$3.3MView ↗
- ▲ +36% (Loss)
- vs −$2.4M in Q2 FY2025
A narrower development pipeline
Earlier descriptions covered therapies for infections, vaccine support, food allergies and organ disease, as well as a rapid diagnostic. The latest report centers on Gemini programs for kidney disease, while describing other potential uses as opportunities to explore.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Feb 26, 2026Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary…View ↗
Revelation is focused on developing potentially high-value products to address significant, unmet medical needs. Revelation’s lead product…View ↗
Our lead Gemini programs have been derisked with preclinical and clinical data and are focused on disorders involving the kidneys including…View ↗
In addition to kidney care, Gemini’s unique immunomodulatory properties could lead to prevention and treatment of a variety of diseases…View ↗
Loading...
